Saturday, April 29, 2017

Just Released | Challenges and Prospects for Clinical Trials in India: A Regulatory Perspective

Challenges and Prospects for Clinical Trials in India: A Regulatory Perspective
by Rahul Mongia, Deepmala Pokhriyal, Seema Rao and Ali Mehdi. ICRIER Health Policy Initiatives, and Academic Foundation, New Delhi, ISBN: 9789332704268. 

Summary: Clinical trials are integral to drug discovery and bringing out newer and better medicines. With the evolution of India's disease burden as well as its pharmaceutical industry, the need for clinical trials has increased manifold. This report analyses prospects and challenges of clinical trials in India, focusing on New Chemical Entities and new drugs, and likewise proposes actionable policy recommendations for the Indian drug regulatory landscape so that the country can realize its untapped potential, while addressing concerns raised regarding the conduct and quality of clinical trials. The Government of India needs to develop a promotive ecosystem around clinical trials now more than ever, sooner rather than later. A clear set of policy, rules and guidelines around clinical trials would be a central component in the larger strategy to address India's public health challenges and incentivize the country's pharmaceutical industry to mature to the next level.

Table of Content

1. Introduction

2. Research Methodology

3. The Dilemmas Afflicting Clinical Research in India

4. Under Trial: The Challenges of Clinical Trials in India

5. Conclusions


neha raje said...

Very Nice information!! I like this Very much !!
#Prorelix #Lifesciences is a #Best #Clinical #Research #Institute in #Pune. Provides continuing education, professional development and vocational short term skills enhancement program.this the #Best clinical institute in #India. Clinical research training in Mumbai,

priya patil said...

Prorelix is one of the best lifescience education institute in india. It provide full, part time courses in pune, Mumbai. Clinical Research Institute in India

priya patil said...
This comment has been removed by the author.